Open AccessOxidized low‐density lipoproteins as a novel risk factor and therapeutic target for ACM
Author(s) -
Tsui Hoyee,
Han Su Ji,
van Rooij Eva
Publication year - 2021
Publication title -
embo molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.923
H-Index - 107
eISSN - 1757-4684
pISSN - 1757-4676
DOI - 10.15252/emmm.202114789
Subject(s) - penetrance , cd36 , pathogenesis , disease , medicine , cardiomyopathy , risk factor , bioinformatics , endocrinology , cardiology , heart failure , chemistry , biology , receptor , gene , biochemistry , phenotype
Arrhythmogenic cardiomyopathy (ACM) is an inherited heart disease involving arrhythmia in young adults accompanied by structural changes at later stages. In this issue of EMBO Molecular Medicine , Sommariva et al (2021) identified a positive correlation between circulating levels of oxidized low‐density lipoproteins (oxLDL) and ACM disease penetrance, which contributes to fibro‐fatty cardiac remodeling via the oxLDL/CD36/PPARγ axis. These data identify oxidized low‐density lipoproteins as a risk factor for ACM and uncover a novel therapeutic intervention option to block disease pathogenesis.